Resistance-Associated Mutations in Chronic Lymphocytic Leukemia Patients Treated With Novel Agents

Resistance-Associated Mutations in Chronic Lymphocytic Leukemia Patients Treated With Novel Agents

Inhibitors of B-cell receptor signaling, ibrutinib and idelalisib, and BCL-2 antagonist, venetoclax, have become the mainstay of treatment for chronic lymphocytic leukemia (CLL). Despite significant efficacy in most CLL patients, some patients develop resistance to these agents and progress on these...

Full description

Bibliographic Details
Main Authors: Lenka Sedlarikova, Anna Petrackova, Tomas Papajik, Peter Turcsanyi, Eva Kriegova
Format: Article
Language:English
Published: Frontiers Media S.A. 2020-06-01
Series:Frontiers in Oncology
Subjects:
CLL
targeted therapy
resistance-associated mutations
treatment resistance
genetic aberrations
Online Access:https://www.frontiersin.org/article/10.3389/fonc.2020.00894/full

Internet

https://www.frontiersin.org/article/10.3389/fonc.2020.00894/full

Similar Items